Skip to main content
Image of syringe and pipets)

Therapeutic Areas and Products

Allergy and Immunology

Our world-leading immunoglobulin (Ig) franchise is the cornerstone of the immunology therapeutic area. Our efforts in this area focus on bringing trusted products and technologies to serve patients with a range of rare and serious diseases, including Primary Immunodeficiencies (PID) and Hereditary Angioedema (HAE).

Key Publications

Efficacy and Safety of a new 20% Immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with Primary Immunodeficiency
Hagan, JB et al
J Clin Immunol

Request | Ask a Question


Efficacy and safety of Hizentra in patients with Primary Immunodeficiency after a dose-equivalent switch from IV or SC replacement therapy
Jolles, S et al
Clinical Immunology, 2011

Request | Ask a Question


Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with Primary Immunodeficiency Diseases
Kanegane, H et al
J Clin Immunol, 2013

Request | Ask a Question


Long-Term efficacy, safety and tolerability of Hizentra for treatment of Primary Immunodeficiency Disease
Jolles, S et al
Clinical Immunology, 2013

Request | Ask a Question


For U.S. Healthcare Professionals only

The purpose of this CSL Behring Medical Affairs website is to support Healthcare Professionals with scientific information. This website is also a channel for U.S. Healthcare Professionals to submit questions or connect with CSL Behring U.S. Healthcare Professionals. The information provided is for educational purposes only and is not intended to promote any products. By continuing to use this site you are acknowledging that you are a US Healthcare Professional